Mats Ehinger is a clinical scientist translating basic immunologic and molecular research to clinical diagnostic practice. His research is focused on developing immunologic and molecular techniques for improved leukemia and lymphoma diagnostics. Dr Ehinger´s research has led to the establishment of several diagnostic methods that today are used in routine clinical practise, particularly for measurement of residual disease in leukemia patients after treatment. Another focus of his research is to improve, simplify and streamline lymphoma diagnostics by applying immunologic and molecular methods on cytologic rather than histologic material. His vision is that future lymphoma diagnostics to a large extent will be possible to perform on cytologic material from fine needle biopsies rather than surgical biopsies with cost-benefit and logistic advantages.

Mats Ehinger is associate professor of hematopathology and senior lecturer of clinical pathology at Lund University where he teaches medical students at the graduate and postgraduate levels. Dr Ehinger also serves as senior consultant pathologist and cytopathologist at the Department of Clinical Genetics and Pathology in Region Skåne Regional Laboratories. His main clinical achievement is the establishment of the hematopathology laboratory in Lund which he also heads. Under his guidance, the laboratory has become recognized for determining measurable residual leukemic disease by the EuroMRD consortium. The laboratory serves as reference center for hematopathology in the southern healthcare region of Sweden. Dr Ehinger is chair of the national quality assurance and standardization group of hematopathology and author of the upcoming WHO international reporting system for lymph node, spleen and thymus cytopathology. He has organized multiple courses in hematopathology at national and international levels, including the XVth EBMWG International Bone Marrow Course and Workshop in Lund 2022 with more than 300 worldwide attendees.